Document Detail


Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
MedLine Citation:
PMID:  16000584     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is a transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated signal transduction. EXPERIMENTAL DESIGN: LPAAT-beta may be a novel target for anticancer therapy, and, thus, we examined the effects of a series of inhibitors of LPAAT-beta on multiple human non-Hodgkin's lymphoma cell lines in vitro and in vivo. RESULTS: We showed that five LPAAT-beta inhibitors at doses of 500 nmol/L routinely inhibited growth in a panel of human lymphoma cell lines in vitro by >90%, as measured by [3H]thymidine incorporation. Apoptotic effects of the LPAAT-beta inhibitors were evaluated either alone or in combination with the anti-CD20 antibody, Rituximab. The LPAAT-beta inhibitors induced caspase-mediated apoptosis at 50 to 100 nmol/L in up to 90% of non-Hodgkin's lymphoma cells. The combination of Rituximab and an LPAAT-beta inhibitor resulted in a 2-fold increase in apoptosis compared with either agent alone. To assess the combination of Rituximab and a LPAAT-beta inhibitor in vivo, groups of athymic mice bearing s.c. human Ramos lymphoma xenografts were treated with the LPAAT-beta inhibitor CT-32228 i.p. (75 mg/kg) daily for 5 d/wk x 4 weeks (total 20 doses), Rituximab i.p. (10 mg/kg) weekly x 4 weeks (4 doses total), or CT-32228 plus Rituximab combined. Treatment with either CT-32228 or Rituximab alone showed an approximate 50% xenograft growth delay; however, complete responses were only observed when the two agents were delivered together. CONCLUSIONS: These data suggest that Rituximab, combined with a LPAAT-beta inhibitor, may provide enhanced therapeutic effects through apoptotic mechanisms.
Authors:
John M Pagel; Christian Laugen; Lynn Bonham; Robert C Hackman; David M Hockenbery; Rama Bhatt; David Hollenback; Heather Carew; Jack W Singer; Oliver W Press
Related Documents :
19842704 - Stereospecific synthesis of alpha-substituted syn-alpha,beta-diamino acids by the diaza...
2029494 - Antithrombin iii-beta associates more readily than antithrombin iii-alpha with uninjure...
8415674 - Purification and characterization of recombinant g16 alpha from sf9 cells: activation o...
7010184 - The e. coli beta-lactamase attenuator mediates growth rate-dependent regulation.
557704 - Effects of aspiculuris tetraptera dn syphacia obvelata on exploratory behavior of an in...
21782904 - Heat shock protein 70 kda over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrid...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  11     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-07     Completed Date:  2005-12-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4857-66     Citation Subset:  IM    
Affiliation:
Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington 98109, USA. jpagel@fhcrc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acyltransferases / antagonists & inhibitors*,  metabolism
Alanine Transaminase / blood
Animals
Antibodies, Monoclonal / administration & dosage,  adverse effects,  pharmacology*
Antigens, CD20 / immunology
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Apoptosis / drug effects*
Aspartate Aminotransferases / blood
Caspases / metabolism
Cell Line, Tumor
Dose-Response Relationship, Drug
Enzyme Inhibitors / administration & dosage,  adverse effects,  pharmacology*
Humans
Hydrocarbons, Halogenated / administration & dosage,  pharmacology*
Injections, Intraperitoneal
Lymphoma, Non-Hodgkin / drug therapy*,  pathology
Mice
Mice, Nude
Mice, SCID
Specific Pathogen-Free Organisms
Survival Analysis
Thymidine / metabolism
Time Factors
Treatment Outcome
Triazines / administration & dosage,  pharmacology*
Tritium
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
K12 CA76930/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/CT-32228; 0/Enzyme Inhibitors; 0/Hydrocarbons, Halogenated; 0/Triazines; 0/rituximab; 10028-17-8/Tritium; 50-89-5/Thymidine; EC 2.3.-/Acyltransferases; EC 2.3.1.52/2-acylglycerophosphate acyltransferase; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands ...
Next Document:  Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite a...